Although our data indicate that Gal-1 and NRP1/EGFR upregulation is a frequent adaptive mechanism in melanoma cells treated with BRAF inhibitors, this signaling cascade may not be critical in every case of melanoma developing drug resistance. The gene discussed is NRP1; the disease is melanoma.